Original Research
22 August 2017

Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial

Publication: Annals of Internal Medicine
Volume 167, Number 6

Abstract

Background:

Continuous glucose monitoring (CGM), which studies have shown is beneficial for adults with type 1 diabetes, has not been well-evaluated in those with type 2 diabetes receiving insulin.

Objective:

To determine the effectiveness of CGM in adults with type 2 diabetes receiving multiple daily injections of insulin.

Design:

Randomized clinical trial. (The protocol also included a type 1 diabetes cohort in a parallel trial and subsequent second trial.) (ClinicalTrials.gov: NCT02282397)

Setting:

25 endocrinology practices in North America.

Patients:

158 adults who had had type 2 diabetes for a median of 17 years (interquartile range, 11 to 23 years). Participants were aged 35 to 79 years (mean, 60 years [SD, 10]), were receiving multiple daily injections of insulin, and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9% (mean, 8.5%).

Intervention:

Random assignment to CGM (n = 79) or usual care (control group, n = 79).

Measurements:

The primary outcome was HbA1c reduction at 24 weeks.

Results:

Mean HbA1c levels decreased to 7.7% in the CGM group and 8.0% in the control group at 24 weeks (adjusted difference in mean change, −0.3% [95% CI, −0.5% to 0.0%]; P = 0.022). The groups did not differ meaningfully in CGM-measured hypoglycemia or quality-of-life outcomes. The CGM group averaged 6.7 days (SD, 0.9) of CGM use per week.

Limitation:

6-month follow-up.

Conclusion:

A high percentage of adults who received multiple daily insulin injections for type 2 diabetes used CGM on a daily or near-daily basis for 24 weeks and had improved glycemic control. Because few insulin-treated patients with type 2 diabetes currently use CGM, these results support an additional management method that may benefit these patients.

Primary Funding Source:

Dexcom.

Get full access to this article

View all available purchase options and get full access to this article.

Supplemental Material

Supplement. Supplemental Information

References

1.
Battelino TPhillip MBratina NNimri ROskarsson PBolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34:795-800. [PMID: 21335621]  doi: 10.2337/dc10-1989
2.
Bergenstal RMTamborlane WVAhmann ABuse JBDailey GDavis SNet alSTAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311-20. [PMID: 20587585]  doi: 10.1056/NEJMoa1002853
3.
Fonseca VAGrunberger GAnhalt HBailey TSBlevins TGarg SKet alConsensus Conference Writing Committee. Continuous glucose monitoring: a consensus conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract. 2016;22:1008-21. [PMID: 27214060]  doi: 10.4158/EP161392.CS
4.
Gandhi GYKovalaske MKudva YWalsh KElamin MBBeers Met al. Efficacy of continuous glucose monitoring in improving glycemic control and reducing hypoglycemia: a systematic review and meta-analysis of randomized trials. J Diabetes Sci Technol. 2011;5:952-65. [PMID: 21880239]
5.
Hommel EOlsen BBattelino TConget ISchütz-Fuhrmann IHoogma Ret alSWITCH Study Group. Impact of continuous glucose monitoring on quality of life, treatment satisfaction, and use of medical care resources: analyses from the SWITCH study. Acta Diabetol. 2014;51:845-51. [PMID: 25037251]  doi: 10.1007/s00592-014-0598-7
6.
Pickup JCFreeman SCSutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011;343:d3805. [PMID: 21737469]  doi: 10.1136/bmj.d3805
7.
Tamborlane WVBeck RWBode BWBuckingham BChase HPClemons Ret alJuvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464-76. [PMID: 18779236]  doi: 10.1056/NEJMoa0805017
8.
Beck RWHirsch IBLaffel LTamborlane WVBode BWBuckingham Bet alJuvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009;32:1378-83. [PMID: 19429875]  doi: 10.2337/dc09-0108
9.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care. 2010;33:17-22. [PMID: 19837791]  doi: 10.2337/dc09-1502
10.
Weiss RGarg SKBode BWBailey TSAhmann AJSchultz KAet al. Hypoglycemia reduction and changes in hemoglobin A1c in the ASPIRE In-Home study. Diabetes Technol Ther. 2015;17:542-7. [PMID: 26237308]  doi: 10.1089/dia.2014.0306
11.
Yeh HCBrown TTMaruthur NRanasinghe PBerger ZSuh YDet al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157:336-47. [PMID: 22777524]
12.
Beck RWRiddlesworth TRuedy KAhmann ABergenstal RHaller Set alDIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317:371-378. [PMID: 28118453]  doi: 10.1001/jama.2016.19975
13.
American Diabetes Association. Statistics About Diabetes: Overall Numbers, Diabetes and Prediabetes. Accessed at www.diabetes.org/diabetes-basics/statistics on 6 February 2016.
14.
Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta: U.S. Department of Health and Human Services; 2014.
15.
Nichols GAGandra SRChiou CFAnthony MSAlexander-Bridges MBrown JB. Successes and challenges of insulin therapy for type 2 diabetes in a managed-care setting. Curr Med Res Opin. 2010;26:9-15. [PMID: 19891525]  doi: 10.1185/03007990903417679
16.
Selvin EParrinello CMDaya NBergenstal RM. Trends in insulin use and diabetes control in the U.S.: 1988-1994 and 1999-2012 [Letter]. Diabetes Care. 2016;39:e33-5. [PMID: 26721815]  doi: 10.2337/dc15-2229
17.
Cariou BFontaine PEschwege ELièvre MGouet DHuet Det al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metab. 2015;41:116-25. [PMID: 25465273]  doi: 10.1016/j.diabet.2014.10.007
18.
Pazos-Couselo MGarcía-López JMGonzález-Rodríguez MGude FMayán-Santos JMRodríguez-Segade Set al. High incidence of hypoglycemia in stable insulin-treated type 2 diabetes mellitus: continuous glucose monitoring vs. self-monitored blood glucose. Observational prospective study. Can J Diabetes. 2015;39:428-33. [PMID: 26254702]  doi: 10.1016/j.jcjd.2015.05.007
19.
Vigersky RAFonda SJChellappa MWalker MSEhrhardt NM. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care. 2012;35:32-8. [PMID: 22100963]  doi: 10.2337/dc11-1438
20.
Haak THanaire HAjjan RHermanns NRiveline JPRayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55-73. [PMID: 28000140]  doi: 10.1007/s13300-016-0223-6
21.
Bailey TSZisser HCGarg SK. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007;9:203-10. [PMID: 17561790]
22.
Garg SJovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care. 2006;29:2644-9. [PMID: 17130198]
23.
Garg SZisser HSchwartz SBailey TKaplan REllis Set al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29:44-50. [PMID: 16373894]
24.
Clarke WLCox DJGonder-Frederick LAJulian DSchlundt DPolonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care. 1995;18:517-22. [PMID: 7497862]
25.
EuroQol Research Foundation. EQ-5D-5L Instruments. Accessed at https://euroqol.org/eq-5d-instruments on 7 July 2017.
26.
Hajos TRPouwer FSkovlund SEDen Oudsten BLGeelhoed-Duijvestijn PHTack CJet al. Psychometric and screening properties of the WHO-5 well-being index in adult outpatients with Type 1 or Type 2 diabetes mellitus. Diabet Med. 2013;30:e63-9. [PMID: 23072401]  doi: 10.1111/dme.12040
27.
Irvine ACox DJGonder-Frederick L. The fear of hypoglycaemia scale. In: Bradley C, eds. Handbook of Psychology and Diabetes. New York: Harwood; 1994:133-55.
28.
Polonsky WHFisher LEarles JDudl RJLees JMullan Jet al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005;28:626-31. [PMID: 15735199]
29.
Polonsky WHFisher LHessler DEdelman SV. Investigating hypoglycemic confidence in type 1 and type 2 diabetes. Diabetes Technol Ther. 2017;19:131-136. [PMID: 27997217]  doi: 10.1089/dia.2016.0366
30.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Validation of measures of satisfaction with and impact of continuous and conventional glucose monitoring. Diabetes Technol Ther. 2010;12:679-84. [PMID: 20799388]
31.
Little RJARubin DB. Statistical Analysis with Missing Data. New York: J Wiley; 1987:164-89, 260-65.
32.
Schafer JL. Analysis of Incomplete Multivariate Data. New York: Chapman & Hall; 1997.
33.
Kleinman LCNorton EC. What's the risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression. Health Serv Res. 2009;44:288-302. [PMID: 18793213]  doi: 10.1111/j.1475-6773.2008.00900.x
34.
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-9. [PMID: 12020338]
35.
Reznik YCohen OAronson RConget IRunzis SCastaneda Jet alOpT2mise Study Group. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet. 2014;384:1265-72. [PMID: 24998009]  doi: 10.1016/S0140-6736(14)61037-0
36.
American Diabetes Association. Standards of medical care in diabetes 2016. Diabetes Care. 2016;39 Suppl 1 S1-S104.

Comments

0 Comments
Sign In to Submit A Comment
Thomas Haak, MD 10 October 2017
Comment
TO THE EDITOR: We welcome Beck and colleagues' trial assessing the effects of continuous glucose monitoring (CGM) in adults with type 2 diabetes receiving multiple daily injections of insulin. The results showed adjusted mean HbA1c reductions in the CGM group of 0.3%1, which was statistically significant but did not meet the investigators’ own definition of clinical significance (defined as a difference of 0.4% or greater between intervention and control group according to the study protocol2). Furthermore, there was no significant difference in CGM-measured hypoglycemia or quality-of-life (QoL) outcomes1.

The authors compared the results of their study with a recent study from our research group using a factory-calibrated CGM device (FreeStyle LibreTM) that showed no significant overall reduction in HbA1c but a significant improvement in time in hypoglycemia and certain QoL measures3. Beck and colleagues suggest that the different outcomes in terms of HbA1c between the two studies could be attributed to alarms with the device used in their study. While they provide no rationale for this hypothesis, we recommend considering the observed HbA1c result in REPLACE in the context of overall outcomes, especially hypoglycemia.

There is clear evidence in REPLACE that the participants significantly reduced hypoglycemia at all thresholds and time intervals analyzed, as this was likely a priority for the study clinicians given the immediate consequences of hypoglycemia versus HbA1c. Beck and colleagues did not report similar decreases in CGM-measured hypoglycemia. Unfortunately, their results are reported in median and interquartile range instead of the more commonly used format of mean and standard deviation, which precludes any conclusions on this outcome.

However, they did observe a slight increase in total daily dose of insulin and body weight of the intervention subjects compared with controls. In REPLACE, there was no statistical difference in total daily dose of insulin for the intervention participants compared with controls and no change in body weight was observed for either group. These findings may be the likely reason for the observed differences in HbA1c between DIAMOND and REPLACE. In our view, it is therefore inappropriate to conclude that the presence of alarms is the basis for the different HbA1c outcomes in the two studies.
It is also noteworthy that independent research has reported an association of real world use of FreeStyle Libre with HbA1c decrease among a population including predominantly insulin-using individuals with type 2 diabetes4.



References:

1. Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, McGill JB, Polonsky W, Price D, Aronoff S, Aronson R, Toschi E, Kollman C, Bergenstal R; DIAMOND Study Group. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Ann Intern Med. 2017 Aug 22. doi: 10.7326/M16-2855. [Epub ahead of print]
2. Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, Kollman C, Kruger D, McGill JB, Polonsky W, Toschi E, Wolpert H, Price D; DIAMOND Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017 Jan 24;317(4):371-378. doi: 10.1001/jama.2016.19975. Supplement 1. http://jamanetwork.com/journals/jama/fullarticle/2598770 [assessed September 21st, 2017]
3. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55-73. [PMID: 28000140] doi:10.1007/s13300-016-0223-6
4. Ish-Shalom, M., Wainstein, J., Raz, I., & Mosenzon, O. (2016). Improvement in glucose control in difficult- to-control patients with diabetes using a novel Flash Glucose Monitoring device. Journal of Diabetes Science and Technology, 5:1572-1583.
Roy Beck, MD, PhD, Tonya Riddlesworth, PhD 31 October 2017
Author's Response
We thank Dr. Haak for his comments.
The treatment group difference used for a sample size calculation is the postulated estimate of the true population value and is not intended to indicate what would be considered clinically significant, a common misconception. The end of the 95% confidence interval on the observed treatment group difference was 0.6%, extending beyond the projected true population value of 0.4%. We believe that a treatment group difference of 0.3% represents a meaningful shift in the HbA1c distributions as evidenced by our finding of 73% of participants achieving a >0.5% reduction in HbA1c at 24 weeks in the CGM group compared with only 49% in the control group.1
Our conjecture that the presence of alerts with the Dexcom system but not the FreeStyle Libre may be an important factor in achieving lower HbA1c levels seems reasonable in the absence of an alternative explanation. Dr. Haak postulated that slight increases in insulin dose (0.1 units/kg/day and in weight (1.3 kg) in our CGM group were a possible explanation for our finding of a significant effect on HbA1c and the REPLACE study2 finding no effect. However, the small insulin increase in our study, even if meaningful, would still be a consequence of CGM use, and it is hard to understand how weight gain would produce a reduction in HbA1c. The central question is not why our study showed a reduction in HbA1c, since CGM has been consistently shown to reduce HbA1c in other populations, but why REPLACE did not.
For hypoglycemia metrics, we believe that median and interquartile range generally are more appropriate than mean and standard deviation due to the fact that the data are almost always skewed, as was the case in both our study and in REPLACE. For comparison purposes between studies, in our study, mean (SD) time <70 mg/dL in the CGM group was 30 (50) minutes/day at baseline and 16 (31) minutes/day at 24 weeks compared with 31 (43) and 27 (40), respectively in the control group. The participants in REPLACE had substantially more baseline hypoglycemia (~74 minutes/day) than the participants in our study (~30 minutes/day), possibly attributable to the low bias of the FreeStyle Libre in hypoglycemia.3 The limited amount of baseline hypoglycemia diminished our ability to statistically demonstrate a hypoglycemia reduction. However, the relative reduction in hypoglycemia in our study was of similar magnitude to that found in REPLACE.

Roy W. Beck, MD, PhD
Tonya Riddlesworth, PhD


References

1. Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, McGill JB, Polonsky W, Price D, Aronoff S, Aronson R, Toschi E, Kollman C, Bergenstal R, DIAMOND Study Group. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Ann Intern Med. 2017 Aug 22. doi: 10.7326/M16-2855. [Epub ahead of print]

2. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55-73. [PMID: 28000140] doi:10.1007/s13300-016-0223-6

3. https://www.accessdata.fda.gov/cdrh_docs/pdf15/p150021b.pdf (accessed October 28, 2017)

Information & Authors

Information

Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 167Number 619 September 2017
Pages: 365 - 374

History

Published online: 22 August 2017
Published in issue: 19 September 2017

Keywords

Authors

Affiliations

Roy W. Beck, MD, PhD
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
Tonya D. Riddlesworth, PhD
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
Katrina Ruedy, MSPH
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
Andrew Ahmann, MD
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
Stacie Haller, RD, LD, CDE
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
Davida Kruger, MSN, APN-BC
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
Janet B. McGill, MD
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
William Polonsky, PhD
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
David Price, MD
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
Stephen Aronoff, MD
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
Ronnie Aronson, MD
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
Elena Toschi, MD
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
Craig Kollman, PhD
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
Richard Bergenstal, MD
From Jaeb Center for Health Research, Tampa, Florida; Oregon Health & Science University, Portland, Oregon; Diabetes & Glandular Disease Clinic, San Antonio, Texas; Henry Ford Medical Center, Detroit, Michigan; Washington University in St. Louis, St. Louis, Missouri; Behavioral Diabetes Institute and Dexcom, San Diego, California; Research Institute of Dallas, Dallas, Texas; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; Joslin Diabetes Center, Boston, Massachusetts;
and Park Nicollet International Diabetes Center, St. Louis Park, Minnesota.
for the DIAMOND Study Group
Financial Support: By Dexcom.
Disclosures: Dr. Beck reports grants from Dexcom during the conduct of the study and other support from Dexcom and Abbott Diabetes Care outside the submitted work. Ms. Ruedy reports grants from Dexcom during the conduct of the study and other fees from Dexcom and Abbott Diabetes Care outside the submitted work. Dr. Ahmann reports grants and personal fees from Dexcom during the conduct of the study; grants from Novo Nordisk, Sanofi, Lexicon, and Medtronic outside the submitted work; and personal fees from Novo Nordisk, Sanofi, Eli Lilly, and Janssen outside the submitted work. Ms. Kruger reports grants from Henry Ford Health System during the conduct of the study; grants from Novo Nordisk, Eli Lilly, Dexcom, and Abbott Diabetes Care outside the submitted work; personal fees from Novo Nordisk, Janssen, Eli Lilly, Boehringer Ingelheim, Sanofi, Dexcom, Abbott Diabetes Care, Intarsia, and AstraZeneca outside the submitted work; and holding Dexcom stock. Dr. McGill reports personal fees from Boehringer Ingelheim, Dexcom, Dynavax, Janssen, Intarcia, Merck, Novo Nordisk, and Valeritas and grants from Dexcom, AstraZeneca/Bristol-Myers Squibb, Novartis, and Lexicon outside the submitted work. Dr. Polonsky reports personal fees from Dexcom during the conduct of the study and from Dexcom and Abbott Diabetes Care outside the submitted work. Dr. Price reports being a Dexcom employee and a shareholder of Dexcom stock. Dr. Aronson reports research support from Merck, Boehringer Ingelheim, Regeneron, Abbott Diabetes Care, Quintiles, ICON, GlaxoSmithKline, Medpace, Novo Nordisk, Janssen, Sanofi, Bristol-Myers Squibb, AstraZeneca, Becton Dickinson, Eli Lilly, Amgen, and Takeda and personal fees from Novo Nordisk, Janssen, Sanofi, AstraZeneca, Becton Dickinson, Eli Lilly, and Amgen outside the submitted work. Dr. Kollman reports grants from Dexcom during the conduct of the study. Dr. Bergenstal reports grants and other fees from Abbott Diabetes Care, Becton Dickinson, Boehringer Ingelheim, Bristol-Myers Squibb/AstraZeneca, Calibra Medical, Eli Lilly, Hygieia, Johnson & Johnson, Medtronic, Novo Nordisk, Roche, Sanofi, Takeda, and Dexcom during the conduct of the study. Dr. Bergenstal is employed by HealthPartners Institute/Park Nicollet Health Services and has contracts with the listed companies for his services as a research investigator or consultant; no personal income from any of these services goes to Dr. Bergenstal. Dr. Bergenstal also reports holding stock in Merck. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-2855.
Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that she has no financial relationships or interests to disclose. Darren B. Taichman, MD, PhD, Executive Deputy Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Pfizer and Johnson & Johnson.
Reproducible Research Statement: Study protocol and statistical code: See the Supplement. Data set: Not available.
Corresponding Author: Roy W. Beck, MD, PhD, Jaeb Center for Health Research, 15310 Amberly Drive, #350, Tampa, FL 33647; e-mail, [email protected].
Current Author Addresses: Drs. Beck, Riddlesworth, and Kollman and Ms. Ruedy: Jaeb Center for Health Research, 15310 Amberly Drive, #350, Tampa, FL 33647.
Dr. Ahmann: Harold Schnitzer Diabetes Health Center, Oregon Health & Science University, 3147 SW Sam Jackson Park Road, Portland, OR 97239.
Ms. Haller: Diabetes & Glandular Disease Clinic, 5107 Medical Drive, San Antonio, TX 78229.
Ms. Kruger: Henry Ford Medical Center Division of Endocrinology, 3031 West Grand Boulevard, Suite 800, Detroit, MI 48202.
Dr. McGill: Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8127, St. Louis, MO 63110.
Dr. Polonsky: Behavioral Diabetes Institute, 5405 Oberlin Drive, Suite 100, San Diego, CA 92121.
Dr. Price: Dexcom, Inc., 6340 Sequence Drive, San Diego, CA 92121.
Dr. Aronoff: Research Institute of Dallas, 10260 North Central Expressway, Suite 100N, Dallas, TX 75231.
Dr. Aronson: LMC Diabetes & Endocrinology, 1929 Bayview Avenue #106, Toronto, Ontario M4G 3E8, Canada.
Dr. Toschi: Joslin Diabetes Center, One Joslin Place, Boston, MA 02215.
Dr. Bergenstal: Park Nicollet Institute, International Diabetes Center, 3800 Park Nicollet Boulevard, St. Louis Park, MN 55416.
Author Contributions: Conception and design: R.W. Beck, K. Ruedy, A. Ahmann, W. Polonsky, D. Price, E. Toschi, C. Kollman, R. Bergenstal.
Analysis and interpretation of the data: R.W. Beck, T.D. Riddlesworth, J.B. McGill, W. Polonsky, D. Price, R. Aronson, E. Toschi, C. Kollman, R. Bergenstal.
Drafting of the article: R.W. Beck, T.D. Riddlesworth, A. Ahmann, S. Haller, D. Price, R. Bergenstal.
Critical revision of the article for important intellectual content: T.D. Riddlesworth, K. Ruedy, S. Haller, D. Kruger, J.B. McGill, W. Polonsky, D. Price, R. Aronson, E. Toschi, C. Kollman, R. Bergenstal.
Final approval of the article: R.W. Beck, T.D. Riddlesworth, K. Ruedy, A. Ahmann, S. Haller, D. Kruger, J.B. McGill, W. Polonsky, D. Price, S. Aronoff, R. Aronson, E. Toschi, C. Kollman, R. Bergenstal.
Provision of study materials or patients: K. Ruedy, A. Ahmann, J.B. McGill, S. Aronoff, R. Aronson, E. Toschi, R. Bergenstal.
Statistical expertise: R.W. Beck, T.D. Riddlesworth, C. Kollman.
Obtaining of funding: D. Price.
Administrative, technical, or logistic support: R.W. Beck, K. Ruedy.
Collection and assembly of data: T.D. Riddlesworth, K. Ruedy, D. Kruger, J.B. McGill, S. Aronoff, R. Aronson, E. Toschi, R. Bergenstal.
This article was published at Annals.org on 22 August 2017.
* For members of the DIAMOND (Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes) Study Group, see the Appendix.

Metrics & Citations

Metrics

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Roy W. Beck, Tonya D. Riddlesworth, Katrina Ruedy, et al; for the DIAMOND Study Group . Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Ann Intern Med.2017;167:365-374. [Epub 22 August 2017]. doi:10.7326/M16-2855

View More

Login Options:
Purchase

You will be redirected to acponline.org to sign-in to Annals to complete your purchase.

Access to EPUBs and PDFs for FREE Annals content requires users to be registered and logged in. A subscription is not required. You can create a free account below or from the following link. You will be redirected to acponline.org to create an account that will provide access to Annals. If you are accessing the Free Annals content via your institution's access, registration is not required.

Create your Free Account

You will be redirected to acponline.org to create an account that will provide access to Annals.

View options

PDF/EPUB

View PDF/EPUB

Related in ACP Journals

Full Text

View Full Text

Figures

Tables

Media

Share

Share

Copy the content Link

Share on social media